Lindsay M. LaFave (Saunders), PhD

Research Fellow

Lindsay M. Saunders, BS

Lab Phone

646-888-2796

Start Year

2009

End Year

2015

Education

University of Michigan

Publications

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. (2016) Reply to “Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status”. Nat Med. 22, 578-9.

LaFave LM, Levine RL. (2016)  Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. Nat Med., 22, 20-1.

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. (2015)  Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med., 21, 1344-9. PMCID: PMC4636469.

Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL. (2014)  Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood, 124, 2280-4. PMCID: PMC4183987.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung Y, Kuscu C, Hricik T, Ndiaye-Lobry D, LaFave L, Koche R, Shih A, Guryanova O, Kim E, Li S, Pandey S, Shin J, Telis L, Liu J, Bhatt P, Monette S, Zhao X, Mason C, Park C, Bernstein B, Aifantis I, Levine R. (2013) Deletion of Asxl1 results in myelodysplasia and sever developmental defects in vivo. J Exp Med210, 2641-2659. PMCID: PMC3832937.

LaFave L, Levine R. (2013) Mining the epigenetic landscape in ALL. Nat Genet45, 1269-1270.

Abdel-Wahab O, Adli M, LaFave L, Gao J, Hricik T, Shih A, Pandey S, Patel J, Chung Y, Koche R, Perna F, Zhao X, Taylor J, Park C, Carroll M, Melnick A, Nimer S, Jaffe J, Aifantis I, Bernstein B, Levine R. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell22, 180-193. PMCID: PMC3422511.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders L, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert B, Chiosis G, Nimer S, Berstein B, Verstovsek S, Levine R. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature489, 155-159. PMCID: PMC3991463.

LaFave L, Levine R. (2012) JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci33, 574-582.

Dey A, Seshasayee D, Noubade R, French D, Liu J, Chaurushiya M, Kirkpatrick D, Pham V, Lill J, Bakalarski C, Wu J, Phu L, Katavolos P, LaFave L, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine R, Dixit V. (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science337, 1541-1546.

Dawson M, Bannister A, Saunders L, Wahab O, Liu F, Nimer S, Levine R, Göttgens B, Kouzarides T, Green A. (2011) Nuclear JAK2. Blood118, 6987-6988.

Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE. (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck, 32, 417-26. PMCID: PMC3292176